|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
41,504,000 |
Market
Cap: |
1.31(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$21.16 - $40.91 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 625 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Collegium Pharmaceutical is a pharmaceutical company. Co.'s portfolio includes: Xtampza ER, Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol. Xtampza ER was approved by the U.S. Food and Drug Administration for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. Nucynta ER is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) ![](../../images/information.jpg) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
181,711 |
216,266 |
332,975 |
1,049,160 |
Total Sell Value |
$6,087,407 |
$7,248,776 |
$10,506,887 |
$26,725,036 |
Total People Sold |
4 |
5 |
6 |
7 |
Total Sell Transactions |
5 |
8 |
14 |
44 |
End Date |
2024-03-24 |
2023-12-22 |
2023-06-23 |
2022-06-23 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Freund John Gordon |
Director |
|
2018-03-19 |
4 |
D |
$0.00 |
$0 |
I/I |
(600,000) |
1,549,916 |
|
- |
|
Heffernan Michael Thomas |
Chairman, President and CEO |
|
2018-02-26 |
4 |
D |
$21.77 |
$88,169 |
D/D |
(4,050) |
590,193 |
|
- |
|
Brannelly Paul |
Executive Vice President & CFO |
|
2018-02-26 |
4 |
D |
$21.77 |
$26,059 |
D/D |
(1,197) |
133,436 |
|
- |
|
Fleming Alison B |
Chief Technology Officer |
|
2018-02-26 |
4 |
D |
$21.77 |
$25,972 |
D/D |
(1,193) |
49,316 |
|
- |
|
Brannelly Paul |
Executive Vice President & CFO |
|
2018-02-05 |
4 |
D |
$23.38 |
$5,003 |
D/D |
(214) |
134,633 |
|
- |
|
Fleming Alison B |
Chief Technology Officer |
|
2018-02-05 |
4 |
D |
$23.38 |
$5,003 |
D/D |
(214) |
50,509 |
|
- |
|
Heffernan Michael Thomas |
Chairman, President and CEO |
|
2018-02-05 |
4 |
D |
$23.38 |
$18,423 |
D/D |
(788) |
594,243 |
|
- |
|
Heffernan Michael Thomas |
Chairman, President and CEO |
|
2018-01-26 |
4 |
A |
$10.17 |
$10,617 |
D/D |
1,044 |
595,031 |
|
- |
|
Brannelly Paul |
Executive Vice President & CFO |
|
2018-01-26 |
4 |
A |
$10.17 |
$10,617 |
D/D |
1,044 |
134,847 |
|
- |
|
Ciaffoni Joseph |
Chief Operating Officer |
|
2018-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
109,268 |
|
- |
|
Heffernan Michael Thomas |
Chairman, President and CEO |
|
2018-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
593,987 |
|
- |
|
Brannelly Paul |
Executive Vice President & CFO |
|
2018-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
133,803 |
|
- |
|
Fleming Alison B |
Chief Technology Officer |
|
2018-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
50,723 |
|
- |
|
Heffernan Michael Thomas |
Chairman, President and CEO |
|
2018-01-23 |
4 |
AS |
$25.01 |
$410,364 |
D/D |
(16,408) |
518,987 |
|
- |
|
Heffernan Michael Thomas |
Chairman, President and CEO |
|
2018-01-22 |
4 |
AS |
$25.00 |
$89,800 |
D/D |
(3,592) |
535,395 |
|
- |
|
Fleming Alison B |
Chief Technical Officer |
|
2018-01-19 |
4 |
AS |
$23.00 |
$76,452 |
D/D |
(3,324) |
156,164 |
|
- |
|
Fleming Alison B |
Chief Technical Officer |
|
2018-01-19 |
4 |
OE |
$0.90 |
$6,484 |
D/D |
3,324 |
157,613 |
|
- |
|
Fleming Alison B |
Chief Technology Officer |
|
2018-01-19 |
4 |
AS |
$23.00 |
$76,728 |
D/D |
(3,336) |
111,419 |
|
- |
|
Fleming Alison B |
Chief Technology Officer |
|
2018-01-19 |
4 |
OE |
$5.73 |
$19,115 |
D/D |
3,336 |
114,755 |
|
- |
|
Heffernan Michael Thomas |
Chairman, President and CEO |
|
2018-01-19 |
4 |
AS |
$22.50 |
$450,000 |
D/D |
(20,000) |
538,987 |
|
- |
|
Fleming Alison B |
Chief Technical Officer |
|
2018-01-12 |
4 |
AS |
$21.00 |
$157,500 |
D/D |
(7,500) |
156,164 |
|
- |
|
Fleming Alison B |
Chief Technical Officer |
|
2018-01-12 |
4 |
OE |
$0.48 |
$4,334 |
D/D |
7,500 |
161,917 |
|
- |
|
Fleming Alison B |
Chief Technology Officer |
|
2018-01-10 |
4 |
AS |
$19.07 |
$132,117 |
D/D |
(6,928) |
25,723 |
|
- |
|
Fleming Alison B |
Chief Technology Officer |
|
2018-01-10 |
4 |
OE |
$0.48 |
$3,325 |
D/D |
6,928 |
32,651 |
|
- |
|
Brannelly Paul |
Executive Vice President & CFO |
|
2017-12-14 |
4 |
GD |
$0.00 |
$0 |
D/D |
2,000 |
108,803 |
|
- |
|
391 Records found
|
|
Page 13 of 16 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|